Definitive Contract 75N91018C00035
Award Date
9/17/18
Potential Completion Date
12/16/21
Potential Value
$350K
Federal Agency
National Cancer Institute
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
<p>The National Cancer Institute, a civilian federal agency, awarded a $1,099,452.64 cost-plus-fixed-fee definitive contract to Zymera Inc., a self-certified small disadvantaged business, for a "HOMOGENEOUS NANO PARTICLE - BASED ASSAYS FOR PROTEASE DETECTION" research and development project under SBIR Phase II Topic No. 266. The contract was set aside for small businesses and has a completion date of June 24, 2015.</p>
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (DHHS), to Theranano LLC, a small disadvantaged, woman-owned business. The $300,000 fixed-price contract is for research on the sustained delivery of PARP inhibitors for cancer chemoprevention. This SBIR contract was issued under the DHHS/NIH/CDC SBIR Contract Solicitation PHS 2018-1, which sought proposals from small...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biocure Inc. for the development of "Targeted Multifunctional Polymersomes for Cancer Therapy". The contract is a Firm Fixed Price Definitive Contract with a ceiling value of $199,889. The period of performance is from the award date of September 30, 2009 to the ultimate completion date of July 31, 2010. This SBIR Phase I contract is focused on...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $288,945 contract was awarded to Vascular Vision Pharmaceutical Co., a woman-owned small business, to conduct research on the topical delivery of nanoformulated bioactive chemopreventive agents for skin cancer. The work is being performed in Wynantskill, NY...
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a civilian agency, to Zymera Inc., a small disadvantaged business. The contract has a ceiling value of $199,948.00 and is for the development of homogeneous nanoparticle-based systems for protease detection. The contract was awarded on September 30, 2009 with a completion date of June 29, 2010. As this is an SBIR Phase I contract, it is a small business set-aside.</p>
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...